Merck to built new pharmaproduction Merck to Invest € 250 Million in Production Value Chain in China
Merck is the first multinational enterprise to dedicate a large-scale green-field investment (€ 170 million) to the production of pharmaceuticals on China’s Essential Drug List. Now the company announced a further invest of 80 million €
Darmstadt, Germany / Nantong, China, November 4, 2016 – Merck, a leading science and technology company, today inaugurated its € 170 million Nantong pharmaceutical plant, which is dedicated to producing high-quality pharmaceuticals on China’s Essential Drug List.
At the inauguration ceremony, Merck also announced a further investment of around € 80 million in a Life Science Center near the Nantong pharmaceutical plant to manufacture high-purity inorganic salts, cell culture media products as well as ready-to-use media.
Strategic Investment in China
The initial € 80 million investment in the pharmaceutical plant was already announced in 2013 and has been realized. The additional investment of € 90 million announced today represents the next phase of Merck’s pharmaceutical production plans for China to meet forecast increased demand for medicines to be produced at the site.
The first drugs from the plant inaugurated today are expected to be delivered to patients in the second half of 2017. Along with the investment of around € 80 million by the Life Science business sector of Merck, this adds up to a total of investment of € 250 million in its production value chain in China to create better access to health.
These strategic investments further support Merck's expansion in China, which is expected to become the world’s second-largest pharmaceutical market by 2018, and enables the company to support the goals of China’s 13th Five Year Plan by investing in technology and developing local talent.
This article is protected by copyright. You want to use it for your own purpose? Contact us at support.vogel.de (ID: 44366504)